2024 Summer Conference | Industry Therapeutic Update from Cartesian Therapeutics: Leveraging the Power of mRNA Cell Therapy for Generalized Myasthenia Gravis

Date Friday 07/19/24

Time 05:30 PM - 06:30 PM EDT Add To Calendar

Location Hilton Atlanta | 208/209

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Milos Miljkovic, MD, Ali A. Habib, MD

Topic(s) General Neurology, Autoimmune Neurology

Learning Objectives Numerous individuals with gMG continue to experience significant disability despite existing treatment options. Within this ITU, the Chief Medical Officer of Cartesian Therapeutics will talk about the differences between conventional and mRNA-based chimeric antigen receptor T-cell therapy (CAR-T) therapy. One of our Sub-Principal Investigators will then highlight the key findings from the recently completed randomized, double-blind, placebo-controlled Phase 2b trial of Descartes-08 in gMG. Lastly, a study team representative will offer insights into the logistical challenges and hurdles faced when initiating a clinical trial within their academic institution.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 Summer Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of preFDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
05:30 PM - 06:30 PM EDT	Speaker	Industry Therapeutic Update from Cartesian Therapeutics: Leveraging the Power of mRNA Cell Therapy for Generalized Myasthenia Gravis

Faculty Disclosures
Milos Miljkovic, MD	Dr. Miljkovic has received personal compensation for serving as an employee of Cartesian Therapeutics. Dr. Miljkovic has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Cartesian Therapeutics. Dr. Miljkovic has stock in Cartesian Therapeutics.
Ali A. Habib, MD	Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for argenx. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD Pharma. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alpine Immune Sciences. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arcellx. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon/ Amgen. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH/NINDS. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunis Biomedical. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman-La Roche. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for argenx. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Habib has received research support from Alexion. The institution of Dr. Habib has received research support from Horizon/Amgen. The institution of Dr. Habib has received research support from Immunovant. The institution of Dr. Habib has received research support from UCB. The institution of Dr. Habib has received research support from argenx. The institution of Dr. Habib has received research support from CabalettaBio. The institution of Dr. Habib has received research support from Genentech. The institution of Dr. Habib has received research support from Regeneron.